Poster Abstract Session:
229. Antimicrobial Resistant Infections: Treatment
Saturday, October 29, 2016: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:


Tracks: Adult ID

Characterization of Piperacillin-tazobactam-Non-Susceptible, but Ceftriaxone-Susceptible, Escherichia coli and Klebsiella pneumoniae Bloodstream Infections
Thomas Baker, MD ; David P. Calfee, MD, MS, FIDSA, FSHEA ; Lars Westblade, PhD ; Stephen Jenkins, PhD ; Barry N. Kreiswirth, PhD ; Michael Satlin, MD
Outcomes on the Use of Daptomycin for the Treatment of Vancomycin-Resistant Enterococcal (VRE) Intra-abdominal Infections (IAI)
Bao Wen Teo, Bachelor of Pharmacy ; Liwen Loo, Bachelor of Pharmacy ; Andrea L. Kwa, PharmD
Daptomycin loading dose, one of the advantageous procedures in a neutropenic murine thigh infection model
Hideo Kato, MS ; Mao Hagihara, PhD ; Jun Hirai, MD ; Naoya Nishiyama, MD ; Yuusuke Koizumi, MD, PhD ; Hiroyuki Suematsu, MS ; Yuka Yamagishi, MD, PhD ; Hiroshige Mikamo, MD, PhD
  • IDweek2016 No.2017.pdf (1.0 MB)
  • Analysis of the Safety and Efficacy of a Colistin Dosing Guideline in the Management of Infections Caused by Multi-Drug Resistant Gram-negative Organisms
    Allison Gibble, PharmD ; Joel Feih, PharmD ; Lauren Fontana, DO ; Sara Revolinski, PharmD, BCPS ; Angela Huang, PharmD, BCPS-AQ ID
    Linezolid versus Daptomycin in the Treatment of Vancomycin-resistant Enterococcal bloodstream infection (VRE-BSI) at a Transplant center
    James a. Mckinnell, MD ; Samantha J. Eells, MPH ; Patil Injean, BS ; Donald Whang, MD ; Romney Humphries, PhD ; Aric Gregson, MD
    In vitro Synergy of Ceftazidime-Avibactam Plus Rifampin Against Pseudomonas aeruginosa
    Diane Sibley, B.S. ; Shelby Simar, B.S. ; Deborah Ashcraft, B.S. ; George Pankey, MD, FIDSA
  • IDSA_Poster.pdf (595.1 kB)
  • Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) in 6 US communities
    Chris Bower, MPH ; Sujan C. Reddy, MD ; Lucy Wilson, MD, ScM ; Elisabeth Vaeth, MPH ; Ghinwa Dumyati, MD, FSHEA ; Cathleen Concannon, MPH ; Erin C. Phipps, DVM, MPH ; Nicole Kenslow, MPH ; Marion Kainer, MBBS, MPH, FSHEA ; Daniel Muleta, MD, MPH ; Jacquelyn Mounsey, BSN, RN, CCRP ; Wendy Bamberg, MD ; Sarah J. Janelle, MPH, CIC ; Elizabeth Badolato, AAS ; Jessica Reno, MPH ; Jesse T. Jacob, MD
    The Impact of Carbapenem Resistance on Resource Utilization in Enterobacteriaceae Infections
    Kristin Dascomb, MD, PhD ; Sean D Firth, PhD, MPH ; Diana Handrahan, BS ; Nicole Hobbs, PhD ; John P. Burke, MD, FIDSA, FSHEA ; Kate Sulham, MPH ; Bert K. Lopansri, MD
    Development of Institution-Specific Sepsis Guidelines for Double Coverage of Gram-Negative Infections
    Dalemarie Vaughan, PharmD, BCPS ; Amy Pakyz, PharmD, MS, PhD ; Michael Stevens, MD, MPH ; Shaina Bernard, PharmD, BCPS
  • Vaughan_IDWeek Poster 2016.pdf (507.3 kB)
  • Factors Affecting Treatment Outcome of Extensively Drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa Infection under Colistin Combination Therapy
    Porpon Rotjanapan, MD ; Parinda Kongprasom, M.D. ; Pakwan Bunupuradah, M.Sc. (Clinical pharmacy) ; Saranya Auparakkitanon, Ph.D. ; Jatupon Krongvorakul, M.D. ; Jetjamnong Sueajai, B.Sc.
    Continuous Infusion of Vancomycin in children with Invasive Methicillin-Resistant Staphylococcus aureus Infections
    Archana Chatterjee, MD, PhD, FIDSA, FPIDS ; Ashlesha Kaushik, MD ; Amy Heiberger, Pharm.D. ; Vishnu Kanala, MD ; Elizabeth Rubin-Peck, MD ; Cassie Wagner, CNP
    Efficacy of oritavancin and comparator agents against vancomycin-resistant Enterococcus faecium in an in vivo Galleria mellonella survival model
    Eric Wenzler, PharmD ; Matthew Deraedt, BS ; Kevin Meyer, BS ; Amanda Harrington, PhD, D(ABMM) ; Larry H. Danziger, Pharm.D., FIDSA
    Daptomycin Nonsusceptible (DapNS) Vancomycin Resistant Enterococcus (VRE) Bloodstream Infections (BSI) in Patients (pt) with Hematologic Malignancies (HM): Risk Factors and Outcomes
    Erica S. Herc, MD ; Bernard L. Marini, PharmD ; Anthony J. Perissinotti, PharmD ; Jose A. Diaz, MD ; Marisa H. Miceli, MD ; Carol A. Kauffman, MD, FIDSA, FSHEA
    Efficacy of Tedizolid in Experimental Myonecrosis caused by Erythromycin/Clindamycin-Sensitive and -Resistant Group A Streptococcus
    Amy Bryant, PhD ; Michael Aldape, PhD ; Clifford Bayer, BS ; Eric Mcindoo, BS ; Dennis Stevens, MD, PhD
    Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug Resistant (XDR) Klebsiella pneumoniae in a Multivisceral Transplant Candidate
    Rossana Rosa, MD ; Susan D. Rudin, BS ; Laura J. Rojas, MSc ; Armando Perez-Cardona, BS ; Laura Aragon, PharmD, BCPS-AQ ID ; David P. Nicolau, PharmD, FCCP, FIDSA ; Federico Perez, MD ; Robert A. Bonomo, MD ; Octavio Martinez, PhD ; Jose Camargo, MD ; Lilian Abbo, MD, FIDSA
  • Kpn_IDW_poster_10222016.pdf (825.1 kB)
  • Antimicrobial Resistance among Campylobacter Isolated from Blood in the United States, 2005–2014
    Jared Reynolds, MPH ; Christy Bennett, BS ; Jennifer Huang, MPH ; Felicita Medalla, MD
    Outcomes with ceftazidime/avibactam in patients with carbapenem-resistant Pseudomonas infections: a multi-center study
    Madeline King, PharmD ; Vanthida Huang, PharmD ; Jason Gallagher, PharmD, FCCP, FIDSA, BCPS ; Emily Heil, PharmD
    The Predictive Utility of Screening VRE Swabs in Selecting Empiric Antibiotics for Sterile-Site Infections
    Ian Brasg, MD ; Marion Elligsen, RPh ; Derek Macfadden, MD ; Nick Daneman, MD, MSc
  • IDWeek 2016 VRE Oct 25.pdf (1.3 MB)
  • Ceftolozane-Tazobactam (C/T) for Severe Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa
    Jose Munita, MD ; Samuel Aitken, PharmD ; Federico Perez, MD ; Rossana Rosa, MD ; Rupali Jain, Pharm.D. ; Masayuki Nigo, MD ; Audrey Wanger, PhD ; Rafael Araos, MD, MMSc ; Truc Tran, PharmD ; Frank P. Tverdek, PharmD ; Luis Shimose, MD ; Paola Lichtenberger, MD ; Javier Adachi, MD, FIDSA ; Lilian Abbo, MD, FIDSA ; Robert Rakita, MD ; Samuel Shelburne, MD, PhD, FIDSA ; Robert A. Bonomo, MD ; Cesar Arias, MD, PhD, FIDSA
    Efficacy of colistin-loaded cement spacer in carbapenem-resistant Klebsiella pneumoniae experimental prosthetic joint infection
    Laure Gatin, MD ; Azzam Saleh-Mghir, PhD ; Frederic Laurent, DPharm, PhD ; Marie-Clémence Verdier, MD ; Idir Ghout, Dr ; Pierre Tattevin, MD, PHD ; Anne-Claude Crémieux, Pr
  • Poster ID week.pdf (566.1 kB)
  • Assessment of Oritavancin Activity in combination with Beta-lactams against Vancomycin-resistant Enterococci
    Francis Arhin, Ph.D. ; David Lalonde Seguin, M.Sc ; Adam Belley, Ph.D. ; Greg Moeck, Ph.D.
  • Arhin et al_2038.pdf (320.7 kB)
  • Cefoxitin (CFX) vs. Piperacillin-Tazobactam (PTZ) for the Treatment of Mild-to-Moderate Complicated Intra-Abdominal Infections (cIAI) in an Era of Increased Anaerobic Resistance
    Nadine Musallam, Pharm.D. ; Caitlin Aberle, Pharm.D. ; Marco R. Scipione, PharmD ; Yanina Dubrovskaya, PharmD ; John Papadopoulos, PharmD
    Minocycline (MINO) Activity is Enhanced by Polymyxin B (PmB) in TetB Containing Isolates of Acinetobacter baumannii (ACB), Including Those Resistant to PmB
    Olga Lomovskaya, PhD ; Kirk Nelson, BS ; Debora Rubio-Aparicio, BS ; Dongxu Sun, PhD ; David Griffith, BS ; Michael N. Dudley, Pharm.D.
    Efficacy of colistin alone and in various combinations for the treatment of carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis
    Pierre Tattevin, MD, PHD ; Azzam Saleh-Mghir, PhD ; Aurelien Dinh, MD ; Laure Gatin, MD ; William Mouton, MD ; Idir Ghout, Dr ; Jacques Ropers, PhD ; Marie-Clémence Verdier, MD ; Frédéric Laurent, PhD ; Patrice Nordmann, MD, PhD ; Anne-Claude Crémieux, Pr
    TetB Testing and its Absence Identifies Minocycline (MINO) Susceptible Isolates of Acinetobacter baumannii (ACB)
    Olga Lomovskaya, PhD ; Dongxu Sun, PhD ; Debora Rubio-Aparicio, BS ; Kirk Nelson, BS ; Michael N. Dudley, Pharm.D.
    Efficacy of Ceftazidime-Avibactam against Multi-Drug Resistant Enterobacteriaceae and Pseudomonas aeruginosa from the Phase 3 Clinical Trial Program
    Gregory G. Stone, PhD ; Leanne Gasink, MD ; Paul Newell, MD ; Helen Broadhurst, MSc ; Angela Wardman, BPharm ; Katrina Yates, PhD
    Clinical and Economic Burden of Multi-drug Resistant Pseudomonas sp. (MDRP) Among Patients with Serious Infections in US Hospitals
    Thomas P. Lodise, PharmD, PhD ; Rosa Wang, MHA ; Tarun Bhagnani, MS ; Qi Zhao, MD, MPH ; Michael Ye, MS ; Ariel Berger, MPH
    Early Experience with Ceftazidime/avibactam at an Academic Medical Center and Affiliated Health System
    Kaitlyn Rivard, PharmD ; Elizabeth Neuner, PharmD ; Vasilios Athans, PharmD ; Andrea Pallotta, PharmD ; Seth Bauer, PharmD ; Stephanie Bass, PharmD ; Eric Cober, MD
    Outcomes with ceftazidime/avibactam in patients with carbapenem-resistant Enterobacteriaceae (CRE) infections: a multi-center study
    Madeline King, PharmD ; Emily Heil, PharmD ; Safia Kuriakose, PharmD ; Tiffany Bias, PharmD, BCPS, AAHIVP ; Vanthida Huang, PharmD ; Claudine El-Beyrouty, PharmD, BCPS ; Dorothy McCoy, PharmD, BCPS AQ-ID ; Jon Hiles, PharmD ; Julianne Gardner, PharmD ; Jason Gallagher, PharmD, FCCP, FIDSA, BCPS
  • CAZAVI for CRE ID week 2016.pdf (480.3 kB)
  • Utility of Therapeutic Drug Management (TDM) in Managing Plazomicin Pharmacokinetic (PK) Variability in Patients with Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE)
    George Daikos, MD ; Spyros Zakynthinos, MD ; Apostolos Komnos, MD ; Maria Souli, MD PhD ; Eleni Antoniadou, MD ; Glykeria Vlachogianni, MD ; Nikolaos Kapravelos, MD ; Alisa Serio, PhD ; Julie Seroogy, MS ; Alex Smith, MS ; Adrian M. Jubb, MBChB, Ph.D., FRCPath ; Antonia Koutsoukou, MD ; Konstantinos Pontikis, MD ; Anna Skiada, MD ; Epaminondas Zakynthinos, MD
  • Poster #2049.pdf (169.4 kB)
  • Choosing Ceftazidime/Avibactam and Ceftolozane/Tazobactam as Empiric Therapies against Pseudomonas aeruginosa (Pa) using Rapid Molecular Diagnostics (RMDs): PRIMERS IV
    Scott Evans, PhD, MS ; Thuy Tien T. Tran, MS ; Andrea Hujer, BS ; Carol Hill, PhD ; Kristine M. Hujer, BS ; Jose R. Mediavilla, MPH, MBS ; Claudia Manca, PhD ; T. Nicholas Domitrovic, BA ; Barry N. Kreiswirth, PhD ; Robin Patel, MD, FIDSA, D(ABMM) ; Michael R. Jacobs, MD, PhD ; Federico Perez, MD ; Liang Chen, PhD ; Rangarajan Sampath, PhD ; Thomas Hall, PhD ; Christine Marzan, PhD ; Vance Fowler, MD ; Henry Chambers, MD, FIDSA ; Robert A. Bonomo, MD
    Clinical Experience with Ceftolozane/Tazobactam at a Large Academic Medical Center
    Gretchen Sacha, PharmD ; Elizabeth Neuner, PharmD ; Vasilios Athans, PharmD ; Andrea Pallotta, PharmD ; Stephanie Bass, PharmD ; Seth Bauer, PharmD ; Kyle Brizendine, MD
    In vitro susceptibility testing of essential oils against carbapenem-resistant Enterobacteriaceae and selected ATCC strains.
    Jan E. Patterson, MD, FIDSA, FSHEA ; Jose Cadena, MD/ID ; Kristi Traugott, PharmD ; Cynthia Kelly, BS, MT(ASCP) ; Steven Dallas, PhD
    Ceftolozane/Tazobactam: Outpatient Treatment of Gram-Negative Infections at Physician Office Infusion Centers (POICs) 
    Ramesh V. Nathan, MD, FIDSA ; Fernando S. Alvarado, MD, FACP, MPH & TM ; Richard C. Prokesch, MD, FACP, FIDSA ; Quyen Luu, MD ; Thomas K. Sleweon, MD ; Claudia P. Schroeder, PharmD, PhD ; Lucinda J. Van Anglen, PharmD
    Significance of Imipenem Tolerance in Cases of Respiratory Tract Infection caused by Pseudomonas aeruginosa.
    Momoyo Azuma, MD, PhD ; Keiji Murakami, MD, PhD ; Yoichiro Miyake, MD, PhD ; Yasuhiko Nishioka, MD, PhD
    Increased detection of blaKPC in Enterobacter cloacae at a New York City Hospital including two emerging clones, ST171 and ST78
    Angela Gomez-Simmonds, MD, MS ; Yue Hu, BS ; Sean Sullivan, MPH ; Zheng Wang, PhD ; Susan Whittier, PhD ; Anne-Catrin Uhlemann, MD, PhD
  • IDweek_poster_10_16ac2.jpg (145.0 kB)
  • Prevalence of mup and qac genes in clinical and surveillance Methicillin-resistant Staphylococcus aureus (MRSA) isolates at two Military treatment facilities
    Mackenzie Morgan, MD ; Emil Lesho, D.O., FIDSA ; Douglas Richesson, PhD ; Ana Ong, BS ; Rossalyn Maybank, BS ; Yoon Kwak, MS ; Michael Julius, PMP ; Mary Hinkle, M.D. ; Patrick Mcgann, PhD
    Estimating the Cost-Effectiveness of Minocycline for the Treatment of Multidrug Resistant Acinetobacter baumannii
    Gemma Kay, BS ; Richard Pitman, PhD ; Weihong Fan, MS ; Shannon Armstrong, BA ; Kate Sulham, MPH
    Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) due to Carbapenem Resistant Enterobacteriaceae: A Report from The Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle)
    Oryan Henig, MD ; David Van Duin, MD, PhD ; Eric Cober, MD ; Sandra S. Richter, MD ; Federico Perez, MD ; Robert Salata, MD ; Robert Kalayjian, MD ; Richard Watkins, MD, MS ; Yohei Doi, MD, PhD ; Scott Evans, PhD, MS ; Vance G Fowler Jr, MD, MHS ; Robert A. Bonomo, MD ; Keith Kaye, MD

    CME Credits: No CME credit is offered for this session.

    ACPE Credits:

    ACPE Number:

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.